Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

35.37 +0.35 (+1.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,113,589
Open 35.13
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 35.02
Today's Range 34.90 - 35.38
52wk Range 34.70 - 53.86
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease
 
Via Benzinga
New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients
 
Via Benzinga

Performance

YTD
-9.93%
-9.93%
1 Month
-6.13%
-6.13%
3 Month
-10.21%
-10.21%
6 Month
-8.58%
-8.58%
1 Year
-29.97%
-29.97%

More News

Read More
Is Roche a Buy Now?
Via The Motley Fool
New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy
Via Benzinga
Roche Introduces Test To Detect Contagious XBB.1.5 Omicron Sub-Variant
Via Benzinga
Daily Stock Analysis: Roche Holding AG
Via Talk Markets
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
Via FinancialNewsMedia
Exposures COVID-19
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
From Genentech
Via Business Wire
FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting
Via Benzinga
The Top 7 Growth Stocks in Biotech
Via InvestorPlace
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
Via Benzinga
Why Sarepta Therapeutics' Shares Rose 23.4% This Week
Via The Motley Fool
3 Best Growth Stocks to Buy In March
Via The Motley Fool
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
Via Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Via Benzinga
Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge
Via Benzinga
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
Via Investor's Business Daily
Biogen Beats Q4 Earnings & Sales Estimates, Stock Up
Via Talk Markets
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
Via Benzinga
New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition
Via Benzinga
Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition
From Genentech
Via Business Wire
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
Via Investor's Business Daily
Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.